Published in:
Open Access
01-12-2016 | Research article
Distribution and prognosis of uncommon metastases from non-small cell lung cancer
Authors:
Fei-Yu Niu, Qing Zhou, Jin-Ji Yang, Wen-Zhao Zhong, Zhi-Hong Chen, Wei Deng, Yan-Yan He, Hua-Jun Chen, Zhu Zeng, E-E Ke, Ning Zhao, Na Zhang, Hui-Wen Sun, Qiu-Yi Zhang, Zhi Xie, Xu-Chao Zhang, Yi-Long Wu
Published in:
BMC Cancer
|
Issue 1/2016
Login to get access
Abstract
Background
According to the literature and our experience, the most common sites of non-small cell lung cancer (NSCLC) metastases include the brain, bone, liver, adrenal glands, contralateral lung and distant lymph nodes. Metastases to other organs are relatively rare. There have been numerous case reports and a few small case series of uncommon metastases derived from NSCLC.
Methods
We defined all organs except the common metastatic sites mentioned above as uncommon sites of metastasis. Patients with uncommon metastases among 2,872 consecutive NSCLC patients with stage IV disease at the Guangdong Lung Cancer Institute (GLCI) from 2006 to 2012 were included in this study. The diagnosis of uncommon metastases was based on pathology or imaging studies.
Results
Uncommon metastases were diagnosed in 193 cases at anatomical sites such as the soft tissue, kidney, pancreas, spleen, peritoneum, intestine, bone marrow, eye, ovary, thyroid, heart, breast, tonsil and nasal cavity. Uncommon metastases were identified as independent poor prognostic factors through a multivariate analysis with a HR (hazard ratio) of 1.29 [95 % confidence interval (CI) 1.09–1.52, P < 0.01]. Those patients who received systemic therapy plus local treatment had a better survival rate than did those who received systemic therapy only (P < 0.01); all patients received best supportive care.
Conclusions
Metastases to the above mentioned sites are infrequent. The presentation of uncommon metastases tends to indicate a poor outcome, and selected patients may benefit from local treatment.